This feature has been funded and written by Accord Healthcare and is intended for UK healthcare professionals only. Prescribing information and Adverse Event Reporting information available at the end of this document.

Few conversations in oncology carry the same immediacy as those that follow a diagnosis of extensive-stage small cell lung cancer - or ES-SCLC. For many patients, the clinical discussion soon narrows to one question:

'How long do I have?'

It’s a question rooted not only in prognosis, but in fear. It is a question about family, work, plans, independence, and the sudden narrowing of a future that may have felt certain only days before.

For healthcare professionals, the question is familiar, but never routine. ES-SCLC is typically aggressive, often diagnosed at an advanced stage, and associated with rapid progression.^1,2 Platinum-based chemotherapy has long formed the backbone of first-line treatment, and while initial responses are common, relapse remains a major challenge.^1,2 In this setting, treatment decisions carry particular weight. When time is limited, improvements in survival must be assessed carefully, communicated accurately, and understood in the context of the patient in front of the clinician.

Building on chemotherapy in the first-line setting

The introduction of immunotherapy into first-line ES-SCLC treatment has added a further dimension to therapeutic decision-making. Following NICE recommendation,³ HETRONIFLY®▼(serplulimab), is the first anti-PD-1 monoclonal antibody indicated in combination with carboplatin and etoposide for the first-line treatment of adult patients with ES-SCLC.⁴

The evidence supporting HETRONIFLY in this setting comes from ASTRUM-005, a phase III, randomised, double-blind, international trial in previously untreated ES-SCLC. The study randomised 585 patients 2:1 to receive HETRONIFLY plus carboplatin and etoposide, n=389, or placebo plus carboplatin and etoposide, n=196. The primary endpoint was overall survival, while the 13 secondary endpoints included progression-free survival, objective response rate, and duration of response.²

The question being tested was clinically direct: could adding HETRONIFLY to platinum-etoposide chemotherapy extend survival compared with chemotherapy alone?

More time, measured carefully

With longer follow-up, ASTRUM-005 continued to show an overall survival benefit with HETRONIFLY plus chemotherapy compared with chemotherapy alone. Median overall survival was 15.8 months in the HETRONIFLY plus chemotherapy group, compared with 11.1 months in the placebo plus chemotherapy group; HR 0.62 (95% CI 0.50–0.76; p<0.001).5 Median progression-free survival was 5.8 months versus 4.3 months; HR 0.47 (95% CI 0.38–0.58; p<0.001).⁵

In ES-SCLC, where conversations often begin with limited time, that difference matters. It represents a separation from what was seen with chemotherapy alone - not as a guarantee for any individual patient - but as evidence that adding HETRONIFLY to chemotherapy extended survival in the clinical study population.

The end-of-study analysis adds further survival benefit. With a median follow-up of 42.4 months, the 4-year overall survival rate was 21.9% (95% CI 17.6–26.6) for patients receiving HETRONIFLY plus chemotherapy, compared with 7.2% (95% CI 3.8–12.1) for those receiving chemotherapy alone.⁶

Of course, these figures are clinical study data, not promises to an individual patient. But in a disease where long-term survival has historically been uncommon, they are clinically meaningful and can be discussed with patients carefully, accurately and without overstatement.¹

For clinicians, this evidence helps structure a difficult conversation. It does not remove uncertainty, nor does it soften the seriousness of ES-SCLC. But it provides data to support a discussion in which survival remains central - and in which additional time can be spoken about accurately, proportionately and with appropriate clinical context.

Safety: part of the same conversation

In ES-SCLC, the focus on survival cannot sit apart from safety. Many patients present with symptoms, comorbidities, frailty, or a high burden of disease. The question is not simply whether a treatment can extend survival in a clinical study population, but whether its benefit–risk profile is acceptable for the individual patient.

In ASTRUM-005, treatment-related adverse events of grade 3 or higher occurred in 33.2% (n=129/389) of patients receiving HETRONIFLY plus chemotherapy and 27.6% (n=54/196) of those receiving chemotherapy alone.² HETRONIFLY demonstrated a good safety profile with manageable adverse events.^2,7 Full details of adverse events, warnings and precautions are available in the Summary of Product Characteristics.

For clinicians, this means safety remains a practical and clinical consideration from the start. It should be discussed clearly, monitored actively, and weighed alongside expected benefit, patient fitness, treatment goals and individual preferences.

Administration in context

HETRONIFLY is administered as an intravenous infusion every three weeks until disease progression or unacceptable toxicity. Treatment must be initiated and supervised by a physician experienced in the treatment of cancer. Please refer to the Summary of Product Characteristics for further information.⁴ In ASTRUM-005, treatment was given with carboplatin and etoposide for four 21-day induction cycles, followed by maintenance HETRONIFLY until disease progression or unacceptable toxicity.²

While administration is an important practical consideration, in ES-SCLC it sits within a broader decision-making context shaped primarily by efficacy, safety and patient suitability.

Returning to the question

No clinician can remove the weight of the question, 'How long do I have?' Nor can trial data provide certainty for the individual sitting in front of them.

What evidence can do is give that conversation structure. It can help clinicians explain what is known, what remains uncertain, and how treatment options compare. In previously untreated ES-SCLC, ASTRUM-005 showed that adding HETRONIFLY to carboplatin and etoposide improved overall survival compared with chemotherapy alone.² With longer follow-up, more patients in the HETRONIFLY plus chemotherapy arm were alive at four years than in the chemotherapy-alone arm.⁶

For clinicians, this does not make the conversation easy, nor does it offer certainty for the individual patient. But it does provide evidence to discuss the possibility of additional time with care, accuracy and appropriate clinical context.

For patients and clinicians facing ES-SCLC, progress is best understood with care: not as overstatement, not as reassurance beyond the evidence, but as an evidence-based extension of what first-line treatment may offer.

You can find more information about HETRONIFLY here

Prescribing information and Adverse Event Reporting information for HETRONIFLY®▼(serplulimab) are available here; for carboplatin are available here; Summary of Product Characteristics for etoposide is available here.

References:

1. Dingemans AMC et al. Ann Oncol 2021: 32(7): 839-53
2. Cheng Y et al. JAMA 2022; 328(12): 1223-32.
3. Serplulimab NICE guidance, June 2026. Available at: https://www.nice.org.uk/guidance/TA1167 (accessed July 2026).
4. HETRONIFLY SmPC, June 2026. Available at: https://accord-healthcare-products.co.uk/products/h/hetronifly-concentrate-for-solution-for-infusion/hetronifly-10-mgml-concentrate-for-solution-for-infusion (accessed July 2026).
5. Cheng Y et al. Cancer Commun (Lond) 2025. DOI: 10.1002/cac2.70032.
6. Cheng Y et al. Poster 214 ASCO Annual Meeting. Chicago, 2025.
7. Zhu Y et al. Ther Adv Med Oncol 2023; 15: 1–16.

Date of preparation: July 2026

Job code: UK-Onc-Het-01591